# Bitterroot Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/bitterroot-bio

- Industry: Biotechnology
- Headquarters: Palo Alto, US
- Website: www.brbio.com
- Total disclosed funding: $147M
- Latest round: Series A (May 3, 2023)
- Investors on record: 5

## About

Based in California, US, and founded in 2021, Bitterroot Bio operates as a biotechnology company that specializes in the development of medicines for individuals suffering from cardiovascular disease. In June 2023, Bitterroot Bio raised USD 145 million in series A funding co-led by ARCH Venture Partners and Deerfield Management.

Bitterroot Bio exists to develop and provide therapies for patients suffering from cardiovascular disease. The company conducts research that identifies the critical roles immune cells and immune modulators play in the development and course of cardiovascular disease by utilizing the immune system's natural disease-fighting capabilities. Furthermore, the research allows the medical community to gain access to appropriate medications, which will advance the treatment of cardiovascular diseases.

The company plans to use the June 2023 funding to develop immunotherapies for cardiovascular diseases

## Funding rounds

- Series A, May 3, 2023, $14M — ARCH Venture Partners, Alexandria Venture Investments, GV, Deerfield Management, Koch Disruptive Technologies
- Series A, Sep 10, 2021, $133M — ARCH Venture Partners, Alexandria Venture Investments, GV, Deerfield Management, Koch Disruptive Technologies

## Investors

- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series A
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series A
- GV (https://capitalatlas.ai/funds/gv) — Series A
- Deerfield Management (https://capitalatlas.ai/funds/deerfield-management) — Series A
- Koch Disruptive Technologies (https://capitalatlas.ai/funds/koch-disruptive-technologies) — Series A